Intuitive Surgical Reports 19% Revenue Growth to $2.89 Billion in Latest Quarter

Intuitive Surgical, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $2.89 billion for the three months ended June 30, 2026, marking a 19% increase from $2.44 billion in the same period last year. The company's net income for the quarter was $818.1 million, up from $658.4 million a year earlier, resulting in a diluted earnings per share of $2.29, compared to $1.81 in the prior year. For the first half of 2026, total revenue was $5.66 billion, a 21% increase from $4.69 billion in the first half of 2025, with net income rising to $1.64 billion from $1.36 billion.

The company experienced notable growth in its product lines, particularly in instruments and accessories, which generated $1.73 billion in revenue for the second quarter, an 18% increase year-over-year. Systems revenue also rose by 19% to $685 million, driven by an increase in da Vinci surgical system placements, which totaled 468 units in the second quarter, up from 395 units in the same period last year. The installed base of da Vinci systems reached approximately 11,710, reflecting a 12% increase from the previous year. Additionally, the Ion endoluminal system saw a 36% increase in procedures performed, totaling approximately 47,900.

Strategically, Intuitive Surgical completed the acquisition of the da Vinci and Ion distribution businesses from ab medica, Abex, and Excelencia Robótica for approximately $533.1 million in cash. This acquisition allows the company to assume direct distribution responsibilities in Italy, Spain, Portugal, and Malta, enhancing its market presence in these regions. The company also reported an increase in its workforce, contributing to higher selling, general, and administrative expenses, which rose by 10% to $617.9 million for the quarter.

Operationally, Intuitive Surgical's gross profit margin improved to 67.8% for the second quarter, up from 66.3% a year prior, attributed to IEEPA tariff refunds and lower logistics costs. The company generated $1.97 billion in cash from operating activities in the first half of 2026, significantly higher than the $1.30 billion reported in the same period of 2025. However, cash and cash equivalents decreased to $2.76 billion as of June 30, 2026, down from $3.37 billion at the end of 2025, primarily due to stock repurchases and the recent acquisition.

Looking ahead, Intuitive Surgical anticipates continued growth driven by increased adoption of its robotic-assisted surgical systems and ongoing expansion into international markets. However, the company remains cautious about potential macroeconomic challenges, including inflationary pressures and supply chain disruptions, which could impact future performance. The company plans to maintain its focus on innovation and expanding its product offerings to enhance patient outcomes and operational efficiencies.